Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

When Emma was diagnosed with triple-negative breast cancer, she didn't let it define her. There are so many ways cancer steals possibility, but at Gilead, we’re helping take it back.

NORTHAMPTON, MA / ACCESS Newswire / May 30, 2025 / Gilead Sciences: We recently commemorated the opening of the Bay Area ...

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries ...

The natural history of chronic hepatitis B virus (HBV) infection is driven by complex interactions among virological, host, ...

Shares of Gilead Sciences Inc. GILD advanced 2.46% to $111.11 Thursday, on what proved to be an all-around positive trading ...

HealthDay News — Herpes simplex virus type 1 (HSV-1) is associated with an increased risk for Alzheimer disease (AD) based on real-world data from the United States, according to a study published ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...

This was the stock's second consecutive day of gains.

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...